Select country change
Shopping cart (0 , 0,00 ) Menu Search
Manufactured by BioVendor

Angiopoietin-Like Protein 4 Human ELISA

  • Regulatory status:RUO
  • Type:Sandwich ELISA, Biotin-labelled antibody
  • Other names:Angiopoietin-related protein 4, Hepatic fibrinogen/angiopoietin-related protein, HFARP, ANGPTL4, ARP4, HFARP, PGAR, PP1158, PSEC0166, UNQ171/PRO197, FIAF
  • Species:Human
Please select your region to see available products and prices.
Cat. No. Size Price


RD191073200R 96 wells (1 kit)
PubMed Product Details
Technical Data

Type

Sandwich ELISA, Biotin-labelled antibody

Applications

Serum, Plasma-EDTA, Plasma-Citrate

Sample Requirements

40 µl/well

Storage/Expiration

Store the complete kit at 2–8°C. Under these conditions, the kit is stable until the expiration date (see label on the box).

Calibration Curve

Calibration Range

0.94–60 ng/ml

Limit of Detection

0.173 ng/ml

Intra-assay (Within-Run)

n = 8; CV = 3.9%

Inter-assay (Run-to-Run)

n = 5; CV = 6.0%

Spiking Recovery

92,40%

Dilutation Linearity

110,90%

Crossreactivity

  • bovine Non-detectable
  • cat Non-detectable
  • dog Non-detectable
  • goat Non-detectable
  • hamster Non-detectable
  • horse Non-detectable
  • monkey Non-detectable
  • mouse Non-detectable
  • rabbit Non-detectable
  • rat Non-detectable
  • sheep Non-detectable
  • chicken Not tested
  • human Yes
  • pig Yes
Summary

Features

  • The total assay time is less than 5 hours
  • The kit measures total Angptl4 in serum and plasma (EDTA, citrate)
  • Assay format is 96 wells
  • Quality Controls are human serum based
  • Standard is recombinant protein based
  • Components of the kit are provided ready to use, concentrated or lyophilized

Research topic

Energy metabolism and body weight regulation

Summary

Angiopoietin-like protein 4 (ANGPTL4) is a secreted 50 kD protein that modulates the disposition of circulating triglycerides (TG) by inhibiting lipoprotein lipase (LPL). ANGPTL4 was identified as a gene that is induced by fasting, and during 3T3-L1 preadipocyte differentiation, and was thus named HFARP (hepatic fibrinogen/an­giopoietin-related protein), FIAF (fasting-induced adipose factor), and PGAR (PPAR-angiopoietin related). It is one of the seven members of the angiopoietin-like family. Angptl4 is expressed ubiquitously, predominantly in adipose tissue, liver, placenta, myocardium, keratinocytes, podocytes, intestine, and pituitary gland. ANGPTL4 is a fusion protein consisting of an N-terminal coiled-coil domain and a C-terminal fibrinogen-like domain. These two domains have been shown to have distinct biological functions. The N-terminal domain is responsible for the inhibitory effects on LPL, converting the active form of LPL into an inactive form, and the C-terminus mediates its antiangiogenic functions. Interestingly, these two domains are separated by a short linker that can be cleaved after secretion. Upon secretion into the circulation, ANGPTL4 is cleaved into an N-terminal domain and a C-terminal fibrinogen-like domain. The N-terminal peptide circulates as an oligomer, and the fibrinogen-like domain circulates as a monomer. The N-terminal domain of ANGPTL4 interacts directly but transiently with LPL, triggering a stable conformational switch in LPL that irreversibly inactivates the enzyme. Cleavage of ANGPTL4 appears to be tissue-dependent in humans; liver secretes cleaved ANGPTL4, whereas adipose tissue secretes the full-length form. In mice the full-length form of ANGPTL4 is physically associated with HDL, whereas truncated ANGPTL4 is associated with low density lipoprotein. In humans, both full-length and truncated ANGPTL4 are associated with HDL. ANGPTL4 expression is upreguated by fasting, free fatty acids, PARR agonists, acute phase response, glucocorticoids, and downregulated by insulin. ANGPTL4 has been implicated in a variety of diseases, including cardiovascular disease, cancer metastasis, obesity, diabetes, wound repair, inflammation, arthritis and nephrotic syndrome. Serum or plasma levels were determined in a limited number of studies. ANGPTL4 serum levels display high variability between individuals ranging from 2 to 158 ng/ml. In post-heparin plasma, ANGPTL4 is increased. ANGPTL4 correlates positively with age, body fat mass, waist-hip-ratio and free faty acids but negatively with plasma high-density lipoprotein cholesterol. No correlation with triglycerides was observed in one study. ANGPTL4 is a positive acute phase protein and its increase could contribute to the hypertriglyce­ridemia that characteristically occurs during the acute phase response by inhibiting LPL activity.

References to Product

References

  • Buzga M, Evzen M, Pavel K, Tomas K, Vladislava Z, Pavel Z, Svagera Z. Effects of the Intragastric Balloon MedSil(R) on Weight Loss, Fat Tissue, Lipid Metabolism, and Hormones Involved in Energy Balance. Obes Surg. 2014 Feb 1;
References to Summary

References to Angiopoietin-Like Protein 4

  • Cazes A, Galaup A, Chomel C, Bignon M, Brechot N, Le Jan S, Weber H, Corvol P, Muller L, Germain S, Monnot C. Extracellular matrix-bound angiopoietin-like 4 inhibits endothelial cell adhesion, migration, and sprouting and alters actin cytoskeleton. Circ Res. 2006 Nov 24;99 (11):1207-15
  • Folsom AR, Peacock JM, Demerath E, Boerwinkle E. Variation in ANGPTL4 and risk of coronary heart disease: the Atherosclerosis Risk in Communities Study. Metabolism. 2008 Nov;57 (11):1591-6
  • Galaup A, Cazes A, Le Jan S, Philippe J, Connault E, Le Coz E, Mekid H, Mir LM, Opolon P, Corvol P, Monnot C, Germain S. Angiopoietin-like 4 prevents metastasis through inhibition of vascular permeability and tumor cell motility and invasiveness. Proc Natl Acad Sci U S A. 2006 Dec 5;103 (49):18721-6
  • Hermann LM, Pinkerton M, Jennings K, Yang L, Grom A, Sowders D, Kersten S, Witte DP, Hirsch R, Thornton S. Angiopoietin-like-4 is a potential angiogenic mediator in arthritis. Clin Immunol. 2005 Apr;115 (1):93-101
  • Kersten S, Lichtenstein L, Steenbergen E, Mudde K, Hendriks HF, Hesselink MK, Schrauwen P, Muller M. Caloric restriction and exercise increase plasma ANGPTL4 levels in humans via elevated free fatty acids. Arterioscler Thromb Vasc Biol. 2009 Jun;29 (6):969-74
  • Le Jan S, Amy C, Cazes A, Monnot C, Lamande N, Favier J, Philippe J, Sibony M, Gasc JM, Corvol P, Germain S. Angiopoietin-like 4 is a proangiogenic factor produced during ischemia and in conventional renal cell carcinoma. Am J Pathol. 2003 May;162 (5):1521-8
  • Robciuc MR, Tahvanainen E, Jauhiainen M, Ehnholm C. Quantitation of serum angiopoietin-like proteins 3 and 4 in a Finnish population sample. J Lipid Res. 2010 Apr;51 (4):824-31
  • Stejskal D, Karpisek M, Reutova H, Humenanska V, Petzel M, Kusnierova P, Vareka I, Varekova R, Stejskal P. Angiopoietin-like protein 4: development, analytical characterization, and clinical testing of a new ELISA. Gen Physiol Biophys. 2008 Mar;27 (1):59-63
  • Sukonina V, Lookene A, Olivecrona T, Olivecrona G. Angiopoietin-like protein 4 converts lipoprotein lipase to inactive monomers and modulates lipase activity in adipose tissue. Proc Natl Acad Sci U S A. 2006 Nov 14;103 (46):17450-5
  • Xu A, Lam MC, Chan KW, Wang Y, Zhang J, Hoo RL, Xu JY, Chen B, Chow WS, Tso AW, Lam KS. Angiopoietin-like protein 4 decreases blood glucose and improves glucose tolerance but induces hyperlipidemia and hepatic steatosis in mice. Proc Natl Acad Sci U S A. 2005 Apr 26;102 (17):6086-91
Related Products Documents